News

Qilu Pharmaceutical (Inner Mongolia) Passes U.S. FDA Inspection

ABOUT US

News

Qilu Pharmaceutical (Inner Mongolia) Passes U.S. FDA Inspection

Release time：

2018-04-14

The USFDA has completed the GMP compliance inspection of Qilu Pharmaceutical (Inner Mongolia), a subsidiary of Qilu Pharma Group. The inspection commenced on April 9, 2018, and was completed on April 12, 2018. All quality systems were evaluated in the inspection, and the facility received a successful response with ZERO FDA 483 observations.The good inspection results speak to our commitment to high standards of quality and excellence.It is the first FDA inspection for Inner Mongolia facilities, which represents an important milestone for the company to enter the US market.

Qilu honored as the top 20 leading enterprise of internationalization

Qilu King-Phar successfully passes the US FDA inspection with no 483 observations

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”